These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7769801)

  • 21. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.
    Pan X; Arauz E; Krzanowski JJ; Fitzpatrick DF; Polson JB
    Biochem Pharmacol; 1994 Aug; 48(4):827-35. PubMed ID: 7521642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium.
    Juan-Fita MJ; Vargas ML; Hernández J
    Eur J Pharmacol; 2005 Apr; 512(2-3):207-13. PubMed ID: 15840406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro pharmacology of R 80122, a novel phosphodiesterase inhibitor.
    Wilhelm D; Wilffert B; Janssens WJ; Leidig A; Meuter C; Ebbert M; Peters T
    J Cardiovasc Pharmacol; 1992; 20(5):705-14. PubMed ID: 1280731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
    Shafiee-Nick R; Pyne NJ; Furman BL
    Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction.
    Muller B; Lugnier C; Stoclet JC
    J Cardiovasc Pharmacol; 1990 Nov; 16(5):796-803. PubMed ID: 1703603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the triazolopyrimidine trapidil on force of contraction, beating frequency and phosphodiesterase I--IV activity in guinea-pig hearts.
    Bethke T; Mehl H; Meyer W; Schmitz W; Scholz H; Thomas K; Wenzlaff H
    Arzneimittelforschung; 1991 May; 41(5):461-8. PubMed ID: 1716891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inotropic responses to selective (RO 20-1724 and SQ 65,442) and nonselective (trequinsin) inhibitors of cyclic AMP-specific class IV phosphodiesterase in newborn, immature, and adult rabbit myocardium.
    Oquist NL; Strada SJ; Artman M
    Pediatr Res; 1992 Mar; 31(3):300-4. PubMed ID: 1313959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. General pharmacological properties of the new vasodilator flosequinan.
    Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers.
    Lues I; Beier N; Jonas R; Klockow M; Haeusler G
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):883-92. PubMed ID: 7687712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of positive inotropic action of flosequinan, hydralazine, and milrinone on mammalian myocardium.
    Miao L; Perreault CL; Travers KE; Morgan JP
    Eur J Pharmacol; 1997 Feb; 321(2):201-8. PubMed ID: 9063689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological and biochemical effects of the cardiotonic agent Org10325 in isolated cardiac and vascular tissue preparations.
    Shahid M; Martorana MG; Cottney JE; Marshall RJ
    Br J Pharmacol; 1990 Aug; 100(4):735-42. PubMed ID: 2169938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incomplete reversal of beta-adrenoceptor desensitization in human and guinea-pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors.
    Wynne DG; Poole-Wilson PA; Harding SE
    Br J Pharmacol; 1993 Aug; 109(4):1071-8. PubMed ID: 7691363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. General pharmacological properties of the main metabolite of flosequinan.
    Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the phosphodiesterase inhibitor enoximone on the autonomic innervation of the isolated heart.
    Löffelholz K; Dressler H; Lindmar R
    J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S33-9. PubMed ID: 2480484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the new phosphodiesterase-III inhibitor R80122 on contractility and calcium current in human cardiac tissue.
    Li Q; Himmel HM; Ravens U
    J Cardiovasc Pharmacol; 1994 Jul; 24(1):133-43. PubMed ID: 7521478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of inotropic selectivity of phosphodiesterase enzyme inhibitors in-vitro.
    Smith GW; Hall JC; West PA
    J Pharm Pharmacol; 1987 Sep; 39(9):748-51. PubMed ID: 2890746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro investigations on a new positive inotropic and vasodilating agent (BM 14.478) that increases myocardial cyclic AMP content and myofibrillar calcium sensitivity.
    Müller-Beckmann B; Freund P; Honerjäger P; Kling L; Rüegg JC
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):8-16. PubMed ID: 2450261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developmental changes in modulation of calcium currents of rabbit ventricular cells by phosphodiesterase inhibitors.
    Akita T; Joyner RW; Lu C; Kumar R; Hartzell HC
    Circulation; 1994 Jul; 90(1):469-78. PubMed ID: 7517800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of cyclic AMP phosphodiesterase activity and myocardial contractility: effects of cilostamide, a novel PDE inhibitor, and methylsiobutylxanthine on rabbit and canine ventricular muscle.
    Endoh M; Satoh K; Yamashita S
    Eur J Pharmacol; 1980 Aug; 66(1):43-52. PubMed ID: 6157546
    [No Abstract]   [Full Text] [Related]  

  • 40. Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts.
    Bethke T; Eschenhagen T; Klimkiewicz A; Kohl C; von der Leyen H; Mehl H; Mende U; Meyer W; Neumann J; Rosswag S
    Arzneimittelforschung; 1992 Apr; 42(4):437-45. PubMed ID: 1386515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.